A specific antidote for dabigatran: functional and structural characterization
Felix Schiele(Boehringer Ingelheim (Germany)), Tobias Litzenburger(Boehringer Ingelheim (Germany)), Eliud Sepulveda(Boehringer Ingelheim (United States)), John Park(California Baptist University), Keith A. Canada(Merck & Co., Inc., Rahway, NJ, USA (United States)), Herbert Nar(Boehringer Ingelheim (Germany)), Joanne van Ryn(Boehringer Ingelheim (Brazil)), Corey Newsome(Boehringer Ingelheim (United States))
Cited by 562
Related Papers
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
|The Lancet Oncology|2018|658
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454